Therakind is attending BIO 2024
Therakind will be attending BIO in San Diego between 3rd and 6th of June. BIO is a renowned conference within the biomedical field that attracts over twenty thousand participants from around the world.
Therakind’s primary aim in BIO this year is to meet potential customers/partners/collaborators for developing dry powder nasal pharmaceutical products. Therakind has a portfolio of dry powder intranasal devices and expertise in formulation development and regulatory strategy. More specifically, Therakind’s novel DriDose Multi-dose Cartridge device is unique as it is reusable and does not require coordinated breathing. We offer a feasibility program, which comprises reformulation and characterisation of a partner’s candidate to evaluate compatibility with Therakind’s nasal device, DriDose.
If you are interested in learning more about the DriDose technology, please reach out to arrange a meeting through the BIO platform:
https://login.partnering.bio.org/inova-business-platform/webclient/#/bio/15601/company/177420
For those interested in partnering with Therakind outside BIO, please contact us at bd@therakind.com
Therakind Contact:
info@therakind.com
Therakind +44 (0) 208 346 6035
About Therakind Limited
Therakind is a specialty pharmaceutical company focused on developing niche medicines in difficult-to-treat markets including paediatric and geriatric patient groups. We have successfully brought three products to marketing approval in the EU, UK and US.
Our proprietary pipeline is focused on improving medicine adherence through more patient-friendly dosing options and we have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to take into account the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups. DriDose®, our intranasal device for the delivery of a dry powder drug formulation is available for co-development. We have also developed a device that is adapted for nasal delivery in a preclinical setting.
To find out more, please visit www.therakind.com
Therakind Sponsors DDL 2023
Therakind is pleased to announce its sponsorship at Drug Delivery to the Lung (DDL) 2023 taking place in Edinburgh between 6th and 8th December. DDL is a renowned respiratory drug delivery conference that attracts over a thousand participants from around the world working in academia and industry.
We will be presenting our DriDose dry powder nasal technology which includes multi-dose, unit dose and preclinical devices, and sharing our expertise in innovative drug delivery. We are introducing new formats of the DriDose technology for the first time at DDL 2023. All devices can be tailored to meet the needs of our partner and the drug candidate.
We are excited to exhibit our devices at DDL 2023 and look forward to exchanging knowledge with professionals in the field. We will be at booth #196- visit us to discuss nasal formulation development and drug delivery.
For those interested in partnering DriDose® with Therakind, please contact us on bd@therakind.com
Therakind Contact:
Therakind +44 (0) 208 346 6035
About Therakind Limited
Therakind is a specialty pharmaceutical company focused on developing niche medicines in difficult-to-treat markets including paediatric and geriatric patient groups.
Our proprietary pipeline is focused on improving medicine adherence through more patient-friendly dosing options and we have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to take into account the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups. DriDose®, our intranasal device for the delivery of a dry powder drug formulation is available for co-development. We have also developed a device that is adapted for nasal delivery in a preclinical setting.
To find out more, please visit www.therakind.com
Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from Therakind
Commercialization to begin in the United States immediately
US- Ireland Pharmaceutical company expands its oral oncology pipeline
October 25, 2023 - CAMBRIDGE, Mass. and London - Shorla Oncology (‘Shorla’), a US-Ireland specialty pharmaceutical company, and Therakind Ltd (‘Therakind’), a UK-based speciality pharmaceutical company have entered into an agreement under which Shorla has agreed to acquire Jylamvo, an oncology and autoimmune drug, for the US market. The therapy has been approved by the US Food and Drug Administration (FDA).
Jylamvo is an easy-to-administer, sweet tasting oral methotrexate solution that eliminates the need for crushing or splitting pills, or compounding into a liquid formulation. A drug that has recently suffered shortages in other dosages forms, Jylamvo is an alternative solution offering advantages over similar drugs because it remains stable at room temperature and does not require cold chain storage. It was approved by the US FDA in 2022 and is used to treat adults with acute lymphoblastic leukemia, mycosis fungoides, relapsed or refractory non-Hodgkin lymphoma, rheumatoid arthritis and severe psoriasis.
“We are delighted to acquire Jylamvo to provide an alternative solution for patients who may have difficulty swallowing pills,” said Sharon Cunningham, chief executive officer of Shorla Oncology. “This is another key step as Shorla grows and commercializes a portfolio of late-stage assets and improves efficiencies by providing more convenient and patient friendly formulations.”
The news comes shortly after Shorla announced that it has raised $35 million in Series B funding to accelerate the growth of its oncology portfolio by bringing therapies to market that will address drug shortages, and improve the preparation and application of oncology medication. This marks Shorla’s second US FDA approved product in its oncology portfolio.
“Therakind is pleased that Jylamvo will now become available to patients in the United States providing a palatable oral liquid alternative to treat a range of indications,” said Susan Conroy, chief executive officer of Therakind.
“This acquisition will provide a much-needed treatment to patients in need,” said Orlaith Ryan, chief technical officer and co-founder of Shorla Oncology. “It brings a crucial oral treatment to a larger patient population who suffer from cancer and other debilitating illnesses.”
About Shorla Oncology
Established in 2018 by Sharon Cunningham and Orlaith Ryan, Shorla Oncology is a privately held, Ireland- and US-based pharmaceutical company with an advanced pipeline of innovative oncology drugs for orphan and pediatric cancers. The company concentrates on indications where existing treatments are limited, in shortage or the drug applications are inadequate for the target population. Shorla's growing portfolio brings accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care.
For further information, please visit www.shorlaoncology.com
Shorla Oncology Contact:
Rachel Ford Hutman
Rachel@fordhutmanmedia.com
+1-301-801-5540
About Therakind Limited
Therakind is a specialty pharmaceutical company focused on developing niche medicines in difficult-to-treat markets including paediatric and geriatric patient groups. Therakind’s proprietary pipeline is focused on improving medicine adherence through more patient friendly dosing options. Therakind has a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to take into account the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups. Jylamvo is Therakind’s third product to gain regulatory approval. For further information, please visit www.therakind.com
Therakind Contact:
Therakind +44 (0) 208 346 6035
Therakind’s DriDose® Dry Powder Intranasal Device Delivers Vaccine
DriDose® has potential to improve adherence in difficult-to-treat patients
March 28 2023 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, today announces the successful results of a pre-clinical immunogenicity study of DriDose®, Therakind’s novel dry powder intranasal device, with Mymetics’ SARS-CoV-2 nasal powder vaccine candidate.
In the pre-clinical study conducted by Mymetics SA, DriDose® has demonstrated efficient delivery of the Mymetics’ SARS-CoV-2 nasal powder vaccine candidate. When compared to the standard nasal applicator used at Mymetics, DriDose® delivered comparable amounts of nasal powder, resulting in comparable serum antibody titres. DriDose® also demonstrated no detectable health or behaviour changes in the pre-clinical model.
DriDose® is a Dry Powder Intranasal Device designed for non-invasive and painless delivery of a dry powder drug formulation. Therakind’s products are specially designed to improve adherence, particularly in difficult-to-treat patient groups. DriDose® is easy to use in a single-handed manner with no specialist training or sterile technique required. The device can be used by physicians, caregivers or patients providing multiple market opportunities. Furthermore, the device is intended to be suitable for administration to unconscious patients as no active inhaling technique is required. The dry powder formulation also enables a long shelf life and potentially avoids cold chain requirements.
Susan Conroy, CEO of Therakind, said: “We are delighted with the results of this initial immunogenicity study with a vaccine. DriDose® offers the potential to deliver vaccines without the use of needles. DriDose® has an important role to play, particularly for difficult-to-treat patients, where treatment adherence is low. We are now progressing additional DriDose® development studies as well as advancing our multi-dose device which offers a low cost, low impact nasal delivery technology.”
Mario Amacker, Head Manufacturing and Quality of Mymetics, said: “I am very pleased to see that the DriDose® applicator delivered comparable immunogenicity and safety results to our standard applicator in this pre-clinical study of our intra-nasal powder vaccine.”
For those interested in partnering DriDose® with Therakind, please contact us on bd@therakind.com
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
Notes to Editors
About Therakind Limited
Therakind is a specialty pharmaceutical company focused on developing niche medicines in difficult-to-treat markets including paediatric and geriatric patient groups.
Our proprietary pipeline is focused on improving medicine adherence through more patient friendly dosing options and we have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to take into account the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups. DriDose®, our intranasal device for the delivery of a dry powder drug formulation is available for co-development. We have also developed a device that is adapted for nasal delivery in a preclinical setting.
To date we have developed and obtained marketing authorisations for three paediatric products, with Jylamvo, our European approved oral methotrexate solution for treating rheumatological and dermatological diseases and acute lymphoblastic leukaemia, also licensed for adults.
To find out more, please visit www.therakind.com
About Mymetics
Mymetics Corporation (OTCQB:MYMX) is a Swiss based biotechnology company, with a research lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious and life disabling diseases. It currently has several vaccines in its pipeline under development, among which are Covid-19, HIV-1/AIDS and malaria, and collaborative projects in the cancer immunotherapy.
Mymetics’ core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. The company’s vaccines are designed to induce protection against early transmission and infection, focusing on both the mucosal and serum immune response. Virosomes have shown to trigger also specific T-cell responses. For further information, please visit www.mymetics.com.
Therakind enters exclusive distribution partnership with Oresund Pharma
Therakind Ltd, a London based specialty pharmaceutical company, has entered into an exclusive distribution partnership with Oresund Pharma ApS, a Danish based specialty pharmaceutical company, for the marketing of Jylamvo in the Nordic countries (Sweden, Finland, Denmark, Iceland, and Norway). Jylamvo has been launched successfully in Norway and Finland and is pending its launch in the remaining Nordic countries.
Jylamvo is a palatable novel methotrexate 2mg/ml oral solution which is licensed for use in adults and children over three years old for the treatment of rheumatological disorders (adult and juvenile) and for the maintenance treatment of acute lymphoblastic leukaemia (ALL), and for adult psoriasis and psoriatic arthritis. Jylamvo has a marketing authorization that allows it to be sold throughout the European Economic Area and was the first oral liquid formulation of methotrexate to be authorised in Europe for the treatment of polyarthritic juvenile idiopathic arthritis (JIA).
Dr. Susan Conroy, CEO of Therakind, said:
“We are delighted to partner with Oresund and expand the European market for Jylamvo. This product provides benefits and choices for both adults and children suffering from rheumatoid arthritis, JIA, psoriasis, or ALL. We are very pleased about the successful launch of Jylamvo in Norway and Finland and look forward to it being available in other Nordic countries”
Therakind collaborates with Indosys to develop a novel dry powder nasal device
Development of a new drug delivery platform
Development of a new drug delivery platform
Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, today announces it has reached an exclusive licensing agreement with Indosys Limited for the development of an innovative dry powder nasal device.
Intranasal medicine delivery not only allows for accurate and consistent dose delivery that achieves rapid, effective blood levels of the administered medication. It also allows for non-invasive, needle-free and painless administration which is suitable for the delivery of small molecules, proteins and peptides. The new device will form the basis of novel delivery platform to be developed exclusively by Therakind.
Susan Conroy, CEO of Therakind, said:
“We are excited to collaborating with Indosys to develop a new delivery system that will enable pain-free delivery of medications, both our own and for future partners. This partnership reflects our passion to work with specialists to design and distribute safe and innovative medicines and delivery devices to improve care through better treatment regimens for patients.”
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
Notes to Editors
About Therakind Limited
Therakind is a specialty pharmaceutical company focused on developing niche products in difficult-to-treat markets including paediatric and geriatric patient groups. We have three paediatric products on the market, with Jylamvo, our European approved oral methotrexate for treating rheumatological and dermatological diseases expanded to treat adults, and DriDose®, our Dry Powder Intranasal Device for the delivery of a dry powder drug formulation available for partnering. Our proprietary pipeline is focused on improving medicine adherence through easier dosing regimens and we have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to take into account the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups.
To find out more, please head to www.therakind.com
Brazilian patent granted for Therakind novel dry powder nasal device DriDose®
Brazil patent granted for Therakind novel dry powder nasal device DriDose®
2nd December 2020 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, today announces that the Brazilian Patent Office has granted approval for the patent application for DriDose®, Therakind’s novel dry powder nasal device.
DriDose® is a Dry Powder Intranasal Device for non-invasive and painless delivery of a dry powder drug formulation. Therakind’s products are specially designed to improve adherence, particularly in difficult-to-treat patient groups. DriDose® is easy to use with no specialist training or sterile technique required in a single-handed operation and can be used by the physician, care-giver or patient themselves, and provides multiple market opportunities. The device can be used on unconscious patients as no active inhaling technique is required and its dry powder formulation enables a long shelf life.
Susan Conroy, CEO of Therakind, said:
“This patent is a key step in the building of our patent portfolio for our DriDose® nasal device. With three Therakind products already on the market, we have a tried and tested strategy to partner our products to ensure the widest outreach possible to patients and the Brazilian market offers an additional out-licensing/distribution opportunity. We believe that DriDose® has the potential to offer a new innovative delivery solution to improve patient adherence in treatment regimens.”
For those interested in partnering DriDose® with Therakind, please contact us on bd@therakind.com
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
Therakind acquires IP to novel dry powder nasal device, DriDose®
DriDose® to form basis of Therakind novel delivery platform
DriDose® to form basis of Therakind novel delivery platform
1st September 2020 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, today announces that it has signed an exclusive agreement with Indosys Limited to acquire the intellectual property for DriDose® an innovative dry powder nasal device.
Intranasal medicine delivery not only allows for accurate and consistent dose delivery, but achieves rapid, effective blood levels of the administered medication. DriDose® is a Dry Powder Intranasal Device for non-invasive and painless delivery of a dry powder drug formulation which is suitable for the delivery of small molecules, proteins, peptides and vaccines. Therakind’s products are specially designed to improve adherence, particularly in difficult-to-treat patient groups. DriDose® is easy to use with no specialist training or sterile technique required in a single-handed operation and can be used by the physician, care-giver or patient themselves, and provides multiple market opportunities. The device can be used on unconscious patients as no active inhaling technique is required and its dry powder formulation enables a long shelf life.
Susan Conroy, CEO of Therakind, said:
“DriDose® provides the basis of a novel delivery platform we are currently developing. It provides key aspects which match our mission to provide new medicines that will improve medicine adherence, particularly in difficult-to-treat patients groups including children, the elderly and those suffering with chronic diseases. We believe with the platform advancements we can bring, DriDose® will offer multiple licensing opportunities across the globe.”
For those interested in partnering DriDose® with Therakind, please contact us on bd@therakind.com
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
Notes to Editors
About Therakind Limited
Therakind is a specialty pharmaceutical company focused on developing niche products in difficult-to-treat markets including paediatric and geriatric patient groups. We have three paediatric products on the market, with Jylamvo, our European approved oral methotrexate for treating rheumatological and dermatological diseases expanded to treat adults, and DriDose®, our Dry Powder Intranasal Device for the delivery of a dry powder drug formulation available for partnering. Our proprietary pipeline is focused on improving medicine adherence through easier dosing regimens and we have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to take into account the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups.
To find out more, please head to www.therakind.com
About Accord Healthcare
Headquartered in the United Kingdom (UK), Accord Healthcare Europe is one of the fastest growing pharmaceutical companies in Europe. Accord has one of the largest market footprints of any European generic and biosimilars companies selling generic medicines in over 80 countries around the world.
This global footprint enables us to deliver vital, affordable medicines to national health systems supporting healthcare professionals to transform patient lives worldwide.
Our approach is agile and inventive, always seeking to improve our products and patients’ access to them. We’re driven to think differently and deliver more for the benefit of patients worldwide.
Therakind acquires IP to novel dry powder nasal device, DriDose®
DriDose® to form basis of Therakind novel delivery platform
DriDose® to form basis of Therakind novel delivery platform
1 September 2020 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, today announces that it has signed an exclusive licensing agreement with Indosys Limited to acquire the intellectual property for DriDose® an innovative dry powder nasal device.
Intranasal medicine delivery not only allows for accurate and consistent dose delivery, but achieves rapid, effective blood levels of the administered medication. DriDose® is a Dry Powder Intranasal Device for non-invasive and painless delivery of a dry powder drug formulation which is suitable for the delivery of small molecules, proteins and peptides. Therakind’s products are specially designed to improve adherence, particularly in difficult-to-treat patient groups. DriDose® is easy to use with no specialist training or sterile technique required in a single handed operation and can be used by physician, care-giver or patient themselves, provide multiple market opportunities. The device can be used on unconscious patients as no active inhaling technique required and its dry powder formulation enables a long shelf life.
Susan Conroy, CEO of Therakind, said:
“DriDose® provides the basis of novel delivery platform we are currently developing. It provides key aspects which match our mission to provide new medicines that will improve medicine adherence, particularly in difficult-to-treat patients groups including children, the elderly and those suffering with chronic diseases. We believe with the platform advancements we can bring, DriDose® will offer multiple licensing opportunities across the globe.”
For those interested in partnering DriDose® with Therakind, please contact us on bd@therakind.com
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
Notes to Editors
About Therakind Limited
Therakind is a specialty pharmaceutical company focused on developing niche products in difficult-to-treat markets including paediatric and geriatric patient groups. We have three paediatric products on the market, with Jylamvo, our European approved oral methotrexate for treating rheumatological and dermatological diseases expanded to treat adults, and DriDose®, our Dry Powder Intranasal Device for the delivery of a dry powder drug formulation available for partnering. Our proprietary pipeline is focused on improving medicine adherence through easier dosing regimens and we have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to take into account the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups.
To find out more, please head to www.therakind.com
Therakind attends Digital BIO 2020
Therakind attends Digital BIO 2020
1 June 2020 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, notes that CEO, Susan Conroy, will be attending Digital BIO 2020 on 8-11 June 2020. https://www.bio.org/press-release/2020-bio-international-convention-now-fully-digital
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centres and related organizations across the United States and in more than 30 other nations.
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
Therakind enters exclusive distribution partnership with BioJam Holding Group
Launch of Jylamvo in Portugal
Launch of Jylamvo in Portugal
14 March 2020 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, has entered into an exclusive distribution agreement with BioJam Holding Group (“BioJam”) for Therakind’s lead product, Jylamvo.
Under this agreement, BioJam secures exclusive rights to market, commercialise and sell Jylamvo in Portugal and Spain, where today the partnership has also announced its successful Launch in Portugal. Jylamvo is already on sale in UK, Middle East, Poland, Romania and Greece.
Jylamvo is a novel methotrexate 2mg/ml Oral Solution which is licensed for use in adults and children over three years old for the treatment of rheumatological disorders (adult and juvenile) and adult psoriasis and psoriatic arthritis, and for the maintenance treatment of acute lymphoblastic leukaemia (ALL). Jylamvo has a marketing authorization which allows it to be sold throughout the European Economic Area and is the first oral liquid formulation of methotrexate to be authorised in Europe for the treatment of polyarthritic juvenile idiopathic arthritis (JIA).
Jylamvo as an oral liquid is easier for patients with swallowing difficulties to take than tablets and its use eliminates dosing inaccuracies and unnecessary exposure to the cytotoxic methotrexate powder which may occur if tablets are crushed. As a licensed oral liquid, Jylamvo has proven stability and no inappropriate excipients which may be the case with unlicensed oral liquids. Jylamvo also has a palatable orange taste which masks methotrexate’s bitter taste. It also addresses compliance issues which may occur with methotrexate injections due to patients’ fear of needles and intolerance of injection site pain and reaction.
Dr Susan Conroy, CEO of Therakind, said:
“We believe in designing medicines tailored to the patient. We are delighted to partner with BioJam and announce the potential availability of Jylamvo, our flagship product, in Spain and Portugal. It is an easy to take, pleasant tasting liquid medicine for children and adults which will simplify their treatment regime. This partnership builds on strategy to partner with specialists in countries who have the expertise and network to broaden access to Jylamvo.”
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
Therakind enters exclusive distribution partnership with Pharmalink
Jylamvo targets United Arab Emirates market
Jylamvo targets United Arab Emirates market
09 January 2020 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, has entered into an exclusive distribution agreement with Pharmalink for Therakind’s lead product, Jylamvo. The partnership also announces today the successful launch of Jylamvo in the UAE.
Under this agreement, Pharmalink secures exclusive rights to market, commercialise and sell Jylamvo in the United Arab Emirates (“UAE”). Jylamvo is already on sale in UK, Greece, Poland and Romania.
Jylamvo is a novel methotrexate 2mg/ml Oral Solution which is licensed for use in adults and children over three years old for the treatment of rheumatological disorders (adult and juvenile) and adult psoriasis and psoriatic arthritis, and for the maintenance treatment of acute lymphoblastic leukaemia (ALL). Jylamvo has a marketing authorization which allows it to be sold throughout the European Economic Area and is the first oral liquid formulation of methotrexate to be authorised in Europe for the treatment of polyarthritic juvenile idiopathic arthritis (JIA).
Jylamvo as an oral liquid is easier for patients with swallowing difficulties to take than tablets and its use eliminates dosing inaccuracies and unnecessary exposure to the cytotoxic methotrexate powder which may occur if tablets are crushed. As a licensed oral liquid, Jylamvo has proven stability and no inappropriate excipients which may be the case with unlicensed oral liquids. Jylamvo also has a palatable orange taste which masks methotrexate’s bitter taste. It also addresses compliance issues which may occur with methotrexate injections due to patients’ fear of needles and intolerance of injection site pain and reaction.
Dr Susan Conroy, CEO of Therakind, said:
“The building of our distribution network is going from strength to strength as we now add Pharmalink to the Therakind family for access to the UAE. For our patients, this means access to medicines designed specifically to meet their needs. Jylamvo is an easy to take, pleasant tasting liquid medicine for children and adults which will simplify their treatment regime. With access in Europe, the UK and the Middle East, our products are gaining a reputation for being safe and effective across the age groups, including children.”
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com